Rob Woodman

At Panakes since 2021, Dr. Rob Woodman has global experience in biotech gained in both institutional and corporate venture firms, encompassing de novo start-up through to growth investments, with a track record of value creation in all of these settings as demonstrated by multiple acquisitions and NASDAQ listings of the companies he has invested in. Previously, Rob was Senior Partner at Takeda Ventures, where he helped build the team and portfolio, sat on the boards of a number of companies including Emendo Bio (acquired by Anges Pharma) and BioMx Inc (NASDAQ: PHGE), and was also the Head of Genesis Labs, Takeda's internal concept incubator. Prior to joining Takeda, Rob was Director of Healthcare Investments at Touchstone Innovations (formerly Imperial Innovations) in London where he led the formation of and investment into a portfolio of UK biotech companies including Enterprise Therapeutics (potentiator programme acquired by Roche) and Inivata (acquired by Neogenomics). Before this, Rob was a Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. Whilst at Sofinnova, he was actively involved in numerous investments throughout Europe and the US, including Ascendis Pharma (NASDAQ; ASND) Omthera Inc (acquired by AstraZeneca).


PhD Oncology - University of Cambridge MSc Biochemistry - University of Oxford

Board membership
Complement Therapeutics DISCO Pharmaceuticals Enterprise Therapeutics Ltd Nouscom